A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

Stopped Despite demonstrated safety and tolerability the trial was terminated early due to program re-prioritization in light of the competitive landscape.

Conditions

• Advanced Cancer
• Solid Tumors
• Acute Myeloid Leukemia Refractory
• Acute Myeloid Leukemia, in Relapse

Interventions

• DRUG: FN-1501

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.